Anti-Human LILRB4 Antibody Pair

Product Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is an inhibitory receptor predominantly expressed on myeloid cells, including monocytes, macrophages, and dendritic cells. This receptor plays a critical role in regulating immune responses by modulating the activation and function of these cells. LILRB4 contains two extracellular immunoglobulin-like domains and is characterized by immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic tail, which facilitate the recruitment of phosphatases that negatively regulate signaling pathways. Dysregulation of LILRB4 has been implicated in several diseases, particularly in cancer and autoimmune disorders. In cancer, high expression levels of LILRB4 on tumor-associated macrophages can create an immunosuppressive microenvironment, aiding tumor progression and evasion of immune surveillance. Additionally, LILRB4 has been associated with systemic lupus erythematosus (SLE) and other inflammatory conditions, where its inhibitory effects may contribute to the dysregulation of immune responses. Protein Function: Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance (PubMed:11875462). Receptor for FN1 (PubMed:34089617). Receptor for apolipoprotein APOE (PubMed:30333625). Receptor for ALCAM/CD166 (PubMed:29263213). Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:9151699). Inhibits FCGR1A/CD64-mediated monocyte activation by inducing phosphatase-mediated down-regulation of the phosphorylation of multiple proteins including LCK, SYK, LAT and ERK, leading to a reduction in TNF production (PubMed:19833736). This inhibition of monocyte activation occurs at least in part via binding to FN1 (PubMed:34089617). Inhibits T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytotoxic T cells and enhancing the generation of CD8+ T suppressor cells (PubMed:16493035, PubMed:19833736, PubMed:29263213). Induces up-regulation of CD86 on dendritic cells (PubMed:19860908). Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation (PubMed:11875462) [The Uniprot Consortium]